A diabetes medication has shown remarkable promise in reducing migraines by more than half, according to a new study. The treatment, liraglutide, a GLP-1 receptor agonist, lowered brain fluid pressure and cut monthly migraine days by over 50%. Researchers believe the key lies in the drug’s ability to reduce intracranial pressure.
In the clinical trial, obese patients with chronic migraines who took liraglutide experienced significant improvements. They reported a 50% reduction in headache days, improved daily functioning, and reduced symptoms of depression and anxiety. The effects were rapid and sustained, with only mild side effects such as nausea and constipation.
The study found that weight loss was not the primary factor behind the improvement. Instead, researchers believe that liraglutide decreases the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide. This could lead to new treatment options for millions worldwide, particularly those who do not respond to current preventives.
A randomized, double-blind trial is now planned by the same research team to further investigate the effectiveness of liraglutide in reducing migraines. If confirmed, this treatment could offer a new hope for people suffering from debilitating migraines.
Source: https://www.dailyrecord.co.uk/lifestyle/health-fitness/diabetes-drug-cuts-migraines-half-35444771